💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Samarium Lexidronam Pentasodium

CHEMBL2110561 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Samarium lexidronam pentasodium is a radiopharmaceutical complex of samarium-153 chelated with ethylenediaminetetramethylene phosphonate (EDTMP), used for pain palliation in patients with osteoblastic bone metastases from cancers such as breast and prostate cancer. The EDTMP phosphonate moiety preferentially localizes samarium-153 to areas of high bone turnover, where the beta emissions deliver local radiation to metastatic lesions. It provides significant pain relief in a substantial proportion of patients with skeletal metastases.

Area Terapeutik

Pain Management Breast Cancer Chronic Pain Prostate Cancer

Mekanisme Kerja

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Samarium lexidronam pentasodium is a radiopharmaceutical complex of samarium-153 chelated with ethylenediaminetetramethylene phosphonate (EDTMP), used for pain palliation in patients with osteoblastic bone metastases from cancers such as breast and prostate cancer. The EDTMP phosphonate moiety preferentially localizes samarium-153 to areas of high bone turnover, where the beta emissions deliver local radiation to metastatic lesions. It provides significant pain relief in a substantial proportion of patients with skeletal metastases.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Samarium Lexidronam Pentasodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110561. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.